Last reviewed · How we verify

octanorm 16.5% — Competitive Intelligence Brief

octanorm 16.5% (octanorm 16.5%) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Human albumin (colloid plasma expander). Area: Critical Care / Hematology.

phase 3 Human albumin (colloid plasma expander) Critical Care / Hematology Biologic Live · refreshed every 30 min

Target snapshot

octanorm 16.5% (octanorm 16.5%) — Octapharma. Octanorm 16.5% is a human albumin solution that restores intravascular oncotic pressure and maintains plasma volume in patients with hypoproteinemia or acute blood loss.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
octanorm 16.5% TARGET octanorm 16.5% Octapharma phase 3 Human albumin (colloid plasma expander)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Human albumin (colloid plasma expander) class)

  1. Octapharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). octanorm 16.5% — Competitive Intelligence Brief. https://druglandscape.com/ci/octanorm-16-5. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: